Navigation Links
Hemoglobinuria in Medical News

Alexion Pharmaceuticals to Present Data on Soliris(R) (Eculizumab) and PNH at the 2007 American Society of Hematology (ASH) Annual Meeting

... that data relating to paroxysmal nocturnal hemoglobinuria (PNH), as well as to Soliris(R) (eculizumab), a ... in Patients with Paroxysmal Nocturnal hemoglobinuria (PNH)" Dr. Peter Hillmen et al. -- ... Disease Burden in Paroxysmal Nocturnal hemoglobinuria Patients with Lower Levels of Hemolysis, ...

Alexion Pharmaceuticals and PDL BioPharma Resolve Patent Dispute

... Union in 2007 as a treatment for patients with paroxysmal nocturnal hemoglobinuria ("PNH"), a rare, debilitating and life-threatening blood disease. The use ... is the first product approved for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) in the U.S. and Europe. PNH is a rare, debilitating, and ...

Researchers to Present Additional Data on Soliris(R) (eculizumab) for the Treatment of PNH at the ASH Annual Meeting

... (eculizumab) as a treatment for patients with paroxysmal nocturnal hemoglobinuria (PNH). Data also have been published regarding initial experience with ... on Ferritin Homeostasis in Eculizumab Treated Paroxysmal Nocturnal hemoglobinuria (PNH) Patients," Dr. Alexander Roeth, et al. Abstract: ...

Alexion Pharmaceuticals Chooses Blue Mountain Regulatory Asset Manager(R) for Best-in-class Calibration Management Integrated with SAP(R)

... targets the immune system). Soliris(R), a humanized monoclonal antibody, is approved in the U.S. and Europe as a treatment for paroxysmal nocturnal hemoglobinuria (PNH), a rare, debilitating and life-threatening blood disease. The company is exploring the use of Soliris(R) as a treatment for patients with other ...
Hemoglobinuria in Medical Technology

PNH Patients With Lower Levels of Hemolysis, Mild Anemia and Minimal Transfusion Support Have Significant Disease Burden; Soliris(R) Therapy Provided Clinical Improvements in PNH Patients Regardless of Disease Severity

... a rare blood disorder called paroxysmal nocturnal hemoglobinuria (PNH), including those who might have been ... Disease Burden in Paroxysmal Nocturnal hemoglobinuria Patients with Lower Levels of Hemolysis, ... Disease Burden in Paroxysmal Nocturnal hemoglobinuria Patients with Lower Levels of Hemolysis, ...

Long-Term Soliris(R) Therapy Improved or Stabilized Kidney Function in Patients With PNH

... a rare blood disorder called paroxysmal nocturnal hemoglobinuria (PNH) were found to be six times more likely than ... in Patients with Paroxysmal Nocturnal hemoglobinuria (PNH)" and "Sustained Improvements in Transfusion ... cytometric analysis of paroxysmal nocturnal hemoglobinuria in the United States and Japan. Medicine ...

PNH Patients Treated with Soliris(TM) Experienced Dramatic Reduction in Blood Clots During Clinical Trials

... first therapy approved for paroxysmal nocturnal hemoglobinuria (PNH), a rare, debilitating and life-threatening ... cytometric analysis of paroxysmal nocturnal hemoglobinuria in the United States and Japan. Medicine ... ischemic infarction in paroxysmal nocturnal hemoglobinuria report of 2 cases and updated review of 7 ...

Alexion Reports Positive Results from AEGIS Registration Study of Soliris in Japanese Patients With PNH

... (eculizumab) treatment of Japanese patients with paroxysmal nocturnal hemoglobinuria (PNH). The pre-specified primary efficacy endpoint of change in hemolysis ... A et al. The incidence and prevalence of paroxysmal nocturnal hemoglobinuria (PNH) and survival of patients in Yorkshire [abstract]. Blood. ...

Soliris(R) Improved Fatigue Independent of Changes in Anemia in Patients with PNH by Controlling Hemolysis

... fatigue and thrombosis with eculizumab treatment in paroxysmal nocturnal hemoglobinuria [abstract]. Blood. 2007;110 (11):1072a. (11) Hill A, Platts PJ, Smith A et al. The incidence and prevalence of paroxysmal nocturnal hemoglobinuria (PNH) and survival of patients in Yorkshire [abstract]. Blood. ...

Alexion Completes Enrollment in AEGIS Registration Study of Soliris(R) (eculizumab) in Patients with PNH in Japan

... as a treatment for Japanese patients with paroxysmal nocturnal hemoglobinuria (PNH). The open-label study, which was authorized by Japan's ... Smith A et al. The incidence and prevalence of paroxysmal nocturnal hemoglobinuria (PNH) and survival of patients in Yorkshire [abstract]. Blood. ...

Soliris(R) Demonstrates Reductions in Hemolysis and Improvements in Fatigue, Overall Quality of Life and Anemia in a Broad Population of PNH Patients

... of patients with a rare blood disorder called paroxysmal nocturnal hemoglobinuria (PNH), according to an analysis of the Phase III SHEPHERD study published ... PJ, Smith A et al. The incidence and prevalence of paroxysmal nocturnal hemoglobinuria (PNH) and survival of patients in Yorkshire [abstract]. Blood. ...

First Clinical Experience With Soliris(R) in Treating Patients With Two Rare Complement-Mediated Diseases Presented at ASH Annual Meeting

... (eculizumab), a terminal complement inhibitor developed by Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN ) for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), was associated with an improvement in hematologic parameters in a limited number of patients with two other rare and severe ...

Alexion Commences Dosing in AEGIS Registration Study of Soliris(R) (eculizumab) in Patients with PNH in Japan

... N Engl J Med. 2006;355:1233-1243. (3) Hill A, Platts PJ, Smith A et al. The incidence and prevalence of paroxysmal nocturnal hemoglobinuria (PNH) and survival of patients in Yorkshire [abstract]. Blood. 2006;108(11):985. (4) Socie G, Mary J Yves, de Gramont A, et al. Paroxysmal ...
Hemoglobinuria in Medical Products

Paroxysmal Nocturnal Hemoglobinuria Profile-WBC

Description: ARUP Laboratories is a national reference laboratory and a worldwide leader in innovative laboratory research and development. ARUP offers an extensive test menu of highly complex and unique medical tests in clinical and anatomic pathology. Owned by the University of Utah, ARUP Laboratories' ...
Company:ARUP Laboratories

Paroxysmal Nocturnal Hemoglobinuria Profile-RBC

Description: ARUP Laboratories is a national reference laboratory and a worldwide leader in innovative laboratory research and development. ARUP offers an extensive test menu of highly complex and unique medical tests in clinical and anatomic pathology. Owned by the University of Utah, ARUP Laboratories' ...
Company:ARUP Laboratories
Hemoglobinuria in Medical Definition

Hematopathology

... stomatocytosis , Warm autoimmune hemolytic anemia , Hemolytic-uremic syndrome , Microangiopathic hemolytic anemia , Paroxysmal nocturnal hemoglobinuria ) • Aplastic anemia : ( Acquired pure red cell aplasia , Fanconi anemia ) • Hemochromatosis Coagulation / platelets DIC • ...

Pathology

... stomatocytosis , Warm autoimmune hemolytic anemia , Hemolytic-uremic syndrome , Microangiopathic hemolytic anemia , Paroxysmal nocturnal hemoglobinuria ) • Aplastic anemia : ( Acquired pure red cell aplasia , Fanconi anemia ) • Hemochromatosis Coagulation / platelets DIC • ...
Hemoglobinuria in Medical Dictionary

Hemoglobinuria

... Paroxysm al cold hemoglobinuria is a condition where antibodies are formed ... blood group. Paroxysm al nocturnal hemoglobinuria (PNH) Definition: Paroxysm al nocturnal hemoglobinuria is a rare, acquired disorder of blood cells in ...

Paroxysm

... Paroxysm al nocturnal hemoglobinuria (PNH) Definition: Paroxysm al nocturnal hemoglobinuria is a rare, acquired disorder of blood cells in ... electrical impulses ... Paroxysm al cold hemoglobinuria is a condition where antibodies are formed ...

Burns

... during major surgery , severe burns with fluid loss through burned skin , ... burns , kidney cancer , malaria , paroxysm al nocturnal hemoglobinuria (dark urine in the morning that lightens up during the day), the hemolytic -uremic syndrome ( HUS ), pyelonephritis , sickle cell anemia ...

Glomerulonephritis

... 1 glomerulonephritis ; ... acute nephritis ( acute glomerulonephritis ), burns , kidney cancer , malaria , paroxysm al nocturnal hemoglobinuria (dark urine in the morning that lightens up during the day), the hemolytic -uremic syndrome ( HUS ), pyelonephritis , ... The most common ...

Haptoglobin

... of hemoglobin in the blood rises above the ability of haptoglobin to reclaim it, hemoglobin begins to appear in the urine -- there is hemoglobinuria . Los niveles de haptoglobin a srica pueden estar disminuidos Puede haber presencia de hemoglobin a en la orina Puede haber presencia de ...

Paronychia

... with paronychia . paronychia parotid duct parotid gland par otitis paroxysm al atria l tachycardia (pat) paroxysm al cold hemoglobinuria paroxysm al nocturnal cephalgia paroxysm al nocturnal dyspnea paroxysm al supra ventricular tachycardia . paroxysm al tachycardia ... ...

Parkinsonism

... to ... parkinsonism paronychia parotid duct parotid gland par otitis paroxysm al atria l tachycardia (pat) paroxysm al cold hemoglobinuria paroxysm al nocturnal cephalgia paroxysm al nocturnal dyspnea paroxysm al supra ventricular tachycardia . ...

More>>

Hemoglobinuria in Biological Technology

PNH Patients Treated with Soliris(TM) Experienced Dramatic Reduction in Blood Clots During Clinical Trials

... first therapy approved for paroxysmal nocturnal hemoglobinuria (PNH), a rare, debilitating and life-threatening ... cytometric analysis of paroxysmal nocturnal hemoglobinuria in the United States and Japan. Medicine ... ischemic infarction in paroxysmal nocturnal hemoglobinuria report of 2 cases and updated review of 7 ...

Soliris(R) Reduced Measures of Thrombosis and Inflammation, and Decreased Indicators of Pulmonary Hypertension, in Studies of Patients with PNH

... on Ferritin Homeostasis in Eculizumab Treated Paroxysmal Nocturnal hemoglobinuria (PNH) Patients" was presented yesterday at the ASH annual meeting by ... PJ, Smith A et al. The incidence and prevalence of paroxysmal nocturnal hemoglobinuria (PNH) and survival of patients in Yorkshire [abstract]. Blood. ...

Alexion Reports Third Quarter 2008 Results

... 2007 and the European Commission (EC) in June 2007, is the only drug specifically indicated for the treatment of patients with paroxysmal nocturnal hemoglobinuria ("PNH"), a rare, debilitating and life-threatening blood disease. The Company reports both GAAP operating results and non-GAAP operating results. ...

Alexion's Soliris(R) Receives 2008 Prix Galien USA Award for Best Biotechnology Product

... be found at: http://www.alexionpharm.com . [ALXN-G] (1) Hill A, Platts PJ, Smith A et al. The incidence and prevalence of paroxysmal nocturnal hemoglobinuria (PNH) and survival of patients in Yorkshire [abstract]. Blood. 2006;108(11):985. (2) Socie G, Mary J Yves, de Gramont A, et al. Paroxysmal ...

Alexion Reports First Quarter 2008 Results

... and the European Commission (EC) in June 2007, is the only drug specifically indicated for the treatment of patients with paroxysmal nocturnal hemoglobinuria ("PNH"), a rare, debilitating and life-threatening blood disease. The Company reports both GAAP results and non-GAAP results. Non-GAAP results are ...

Alexion Reports Fourth Quarter and Full Year 2007 Results

... 2007 and the European Commission in June 2007, is the only drug specifically indicated for the treatment of patients with paroxysmal nocturnal hemoglobinuria ("PNH"), a rare, debilitating and life-threatening disease. A portion of the Soliris product sold in the fourth quarter was previously accounted ...

Alexion Acquires All Rights to OMRF Patents Related to Soliris(R)

... during 2007. Soliris(R) (eculizumab) is a complement inhibitor product developed and marketed by Alexion for the treatment of paroxysmal nocturnal hemoglobinuria ("PNH"), a rare, debilitating and life-threatening disease. "Soliris opened a major new therapeutic avenue for patients with PNH, and the ...
Other Contents
(Date:7/28/2015)... ... July 28, 2015 , ... The joint SCAN ... such as reducing high-risk medication use and improving compliance with diabetes treatment guidelines. ... behaviors and outcomes, this unique-in-the-industry Quality Network Program may be paving the way ...
(Date:7/28/2015)... ... July 28, 2015 , ... Headaches are the number one neurological ... close second. Clients suffering from headaches and back pain often find relief by seeking ... The Joint 's nine offices in the St. Louis area welcome new clients ...
(Date:7/28/2015)... ... 28, 2015 , ... North American Seminars will present seventeen ... 2015 . These seventeen courses are pre-approved for CME credit for Physical ... in the Older Adult , August 22, 2015 - August 23, 2015 ...
(Date:7/28/2015)... ... July 28, 2015 , ... ... for Invisalign. Invisalign is a revolutionary orthodontic treatment that allows patients to straighten ... Mozafari’s expertise and 3D computer imaging technology. You wear each set of aligners ...
(Date:7/27/2015)... ... July 28, 2015 , ... Dr. Robert G. Schwartz ... practice has teamed up with Realief Neuropathy Centers in order to offer his patients ... the signs and symptoms of peripheral neuropathy. , Peripheral neuropathy is a disease caused ...
Breaking Medicine News(10 mins):Health News:SCAN/Express Scripts MA Pharmacy Quality Network Program to be Featured in Upcoming AIS Webinar 2Health News:SCAN/Express Scripts MA Pharmacy Quality Network Program to be Featured in Upcoming AIS Webinar 3Health News:The Joint St. Louis Offers “2 for Thursday” Special, Chiropractic Care Services, Affordable Back Pain Relief 2Health News:North American Seminars receives California PT Board approval for Seventeen Continuing Education Courses presented in the Fall of 2015. 2Health News:North American Seminars receives California PT Board approval for Seventeen Continuing Education Courses presented in the Fall of 2015. 3Health News:North American Seminars receives California PT Board approval for Seventeen Continuing Education Courses presented in the Fall of 2015. 4Health News:North American Seminars receives California PT Board approval for Seventeen Continuing Education Courses presented in the Fall of 2015. 5Health News:North American Seminars receives California PT Board approval for Seventeen Continuing Education Courses presented in the Fall of 2015. 6Health News:North American Seminars receives California PT Board approval for Seventeen Continuing Education Courses presented in the Fall of 2015. 7Health News:North American Seminars receives California PT Board approval for Seventeen Continuing Education Courses presented in the Fall of 2015. 8Health News:Cupertino Invisalign Dentist, Dr. Setareh Mozafari, is Now Offering Complimentary Consultations for Invisalign 2Health News:Piedmont Physical Medicine & Rehabilitation, P.A. Partners with Realief® Neuropathy Centers to Offer Peripheral Neuropathy Laser Treatment 2
(Date:7/9/2015)... SAN JOSE, Calif. , July 9, ... ), the leading developer of human interface ... authentication technology, the industry,s first fully hardware ... innovative Match-in-Sensor secure authentication technology is literally ... pattern storage and biometric matching within the ...
(Date:7/8/2015)... SAN DIEGO , July 8, 2015 /PRNewswire/ ... of cell-free molecular diagnostics, today announced the launch ... of the Company,s Precision Cancer Monitoring℠ (PCM) technology ... patients receiving one or a combination of the ... and Opdivo® (nivolumab), a PD-1 inhibitor. The 50-patient ...
(Date:7/7/2015)... , July 7, 2015  Based on its ... & Sullivan recognizes Credence ID, LLC with the ... Company of the Year Award. Credence ID has ... in its mission of offering enrollment and identification ... As Credence ID was formed by experts from ...
Breaking Biology News(10 mins):Synaptics Announces World's First Match-in-Sensor Fingerprint Authentication Technology 2Synaptics Announces World's First Match-in-Sensor Fingerprint Authentication Technology 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 2Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 4Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 2Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 3Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 4Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 5
Other TagsOther Tags